What question did this study set out to answer?

Evaluate the cost-effectiveness of triple versus dual-drug therapy for lymphatic filariasis elimination in India.

March 14, 2026Open Access

Cost-Effectiveness of Triple Versus Dual-Drug Therapy for Elimination of Lymphatic Filariasis in India

JKJeyaram KaviyaKalam Institute of Health Technology VSVanjavakam SahithyaKalam Institute of Health Technology AJAnisha Mary JohnKalam Institute of Health Technology

Key Points

Evaluate the cost-effectiveness of triple versus dual-drug therapy for lymphatic filariasis elimination in India.
Comparative analysis of triple and dual-drug therapy
Assessment of health outcomes and cost savings
IDA found to be more cost-effective than DA
Better health outcomes associated with IDA
Supporting evidence for IDA in Mass Drug Administration programs

Abstract

We found that IDA is cost-effective, when compared with DA, offering better health outcomes and long-term cost savings. These findings support the adoption of IDA in Mass Drug Administration programs, promoting efficient resource use and advancing LF elimination goals by 2027.

Perguntar à IA

Bookmark

View Full Paper